Valproic acid-associated vanishing bile duct syndrome

Journal of Child Neurology

Volumn 25, Issue 7, 2010, Pages 909-911

  Gökçe, Selim ^a   Durmaz, Özlem ^a   Çeltik, Coşkun ^a   Aydoǧan, Ayşen ^a   Güllüoǧlu, Mine ^a   Sökücü, Semra ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

bile duct loss; jaundice; valproic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CYTOKERATIN 7; CYTOKERATIN 9; GAMMA GLUTAMYLTRANSFERASE; MICROSOME ANTIBODY; SMOOTH MUSCLE ANTIBODY; URSODEOXYCHOLIC ACID; VALPROIC ACID; ANTICONVULSIVE AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT DISEASE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHILD; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONVULSION; DISEASE DURATION; DRUG WITHDRAWAL; ECHOGRAPHY; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LIVER BIOPSY; LIVER TOXICITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; SCHOOL CHILD; VANISHING BILE DUCT SYNDROME; XANTHOMA; CHEMICALLY INDUCED; METABOLISM; PATHOLOGY;

ANTICONVULSANTS; BILE DUCT DISEASES; CHILD; FEMALE; HUMANS; VALPROIC ACID;

EID: 77954415258     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073809343474     Document Type: Article

References (16)

1. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia. 1998 ; 39 (11). 1216-1225.
2. Rettie AE, Rettenmeier AW, Howald WN, Baillie TA. Cytochrome P450-catalyzed formation of delta-4-VPA, a toxic metabolite of valproic acid. Science. 1987 ; 235 (4791). 890-893.
3. Davison S. Chronic hepatitis. In: Kelly DA, ed. Diseases of the Liver and Biliary System in Children. 2 nd ed. Oxford, UK: Blackwell Publishing Ltd ; 2004: 127-161.
4. Dreifuss FE, Langer DH, Moline KA, Maxwell JE Valproic acid hepatic fatalities II. United States experience since 1984. Neurology. 1989 ; 39 (2, pt 1). 201-207.
5. Suchy FJ, Balistreri WF, Buchino JJ, et al. Acute hepatic failure associated with the use of sodium valproate. N Engl J Med. 1979 ; 300 (17). 962-966.
6. Srivastava M., Perez-Atayde A., Jonas MM Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology. 1998 ; 115 (3). 743-746. (Pubitemid 28397310)
7. Pirmohamed M., Kitteringham NR, Breckenridge AM, Park BK Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol. 1992 ; 33 (2). 183-186.
8. Garcia M., Mhanna MJ, Chung-Park MJ, Davis PH, Srivastava MD Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes. Dig Dis Sci. 2002 ; 47 (1). 177-182. (Pubitemid 34075036)
9. Desmet VJ Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol. 1997 ; 26 (suppl 1). 31-35. (Pubitemid 127777235)
10. Verdine L., Biance N., Souleau B., Nedellec G., de Revel T. Agranulocytosis and simultaneous cholestatic jaundice induced by sodium valproate in an elderly woman. Presse Med. 2001 ; 30 (28). 1404. (Pubitemid 32952463)
11. Bach N., Thung SN, Schaffner F., Tobias H. Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate. Dig Dis Sci. 1989 ; 34 (8). 1303-1307. (Pubitemid 19202130)
12. Mohi-ud-din R., Lewis JH Drug and chemical-induced cholestasis. Clin Liver Dis. 2004 ; 8 (1). 95-132.
13. Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002 ; 36 (3). 525-531. (Pubitemid 34977162)
14. Jakab SS, West AB, Meighan DM, Brown RS, Hale WB Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol. 2007 ; 13 (45). 6087-6089. (Pubitemid 350238281)
15. Morelli MS, OBrien FX Stevens-Johnson Syndrome and cholestatic hepatitis. Dig Dis Sci. 2001 ; 46 (11). 2385-2388.
16. Lazaridis KN, Gores GJ, Lindor KD Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol. 2001 ; 35 (1). 134-146. (Pubitemid 32646237)